Cytokinetics Stock News

Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting

In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the  Top 5 Healthcare Stocks for the Future .

Company Committed to Advancing Omecamtiv Mecarbil with Initial Focus on Preparation s for Regulatory Interaction s Following Positive Results of GALACTIC-HF

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Amazon and Yelp.

Appointment Strengthens Commercial, Market Access and Specialty Sales Expertise as Company Advances Pipeline Toward Potential Commercialization Appointment Strengthens Commercial, Market Access and Sp

New Findings from Studies of Cardiac Myosin Inhibitors in Animal Models of Hypertrophic Cardiomyopathy and Heart Failure with Preserved Ejection Fraction New Findings from Studies of Cardiac Myosin In

Trial Met Primary Composite Endpoint of Reduction in Heart Failure Events or Cardiovascular Death; Did Not Meet Secondary Endpoints Including Reduction in Cardiovascular Death

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 30, 2020 it granted stock options to purchase an aggregate of 2

Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session

Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q3 2020 Results - Earnings Call Transcript

Biogen has embraced Ionis antisense technology for neurology targets. A new Gene Therapy Accelerator Unit was formed last year and has facilitated the creation of new business units and collaborations

Sanders Morris Harris LLC bought a new position in shares of Cytokinetics, Inc. (NASDAQ:CYTK) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Co

Equities analysts expect Cytokinetics, Inc. (NASDAQ:CYTK) to post $3.80 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Cy

Cytokinetics, Inc. (NASDAQ:CYTK) CEO Robert I. Blum sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 13th. The stock was sold at an average price of $15.94, for a total val

Cytokinetics, Inc. (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 1,258 shares of the stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $17.45, for a total tra